Home
    Disclaimer
    25H-NBOMe molecular structure

    25H-NBOMe Stats & Data

    25h 2c-h-nbome Nbome-2c-h 25-h-nbome
    NPS DataHub
    MW301.39
    FormulaC18H23NO3
    CAS919797-16-3
    IUPAC2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
    SMILESCOc1ccc(OC)c(CCNCc2ccccc2OC)c1
    InChIKeyRMLXCDMTGWSEOU-UHFFFAOYSA-N
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic / Stimulant
    Half-Life Unknown in humans; by analogy with other NBOMes estimated 2–4 h for parent with potential active metabolites prolonging effects.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial, unusually selective)
    5-HT2B receptor agonist (cardiotoxic)

    Effect Profile

    Curated + 1 Reports
    Psychedelic 5.2

    Strong body load and visuals with moderate headspace

    Visual Intensity×3
    8
    Headspace Depth×3
    6
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    10
    Stimulant 3.6

    Strong anxiety/jitters with mild stimulation and focus, low euphoria

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    3
    Focus / Productivity×2
    4
    Anxiety / Jitters×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; by analogy with other NBOMes estimated 2–4 h for parent with potential active metabolites prolonging effects.
    Addiction Potential
    Very low; produces little reinforcing euphoria yet some users report psychological craving for novelty. No documented physical dependence.

    Tolerance Decay

    Full tolerance 0h Half tolerance 3d Baseline ~14d

    Cross‑tolerance among serotonergic psychedelics is expected due to 5‑HT2A receptor desensitization. Many users report markedly blunted effects if re‑dosing within 1–2 weeks after NBOMe exposure; some describe longer cross‑tolerance windows with higher doses. Data remain anecdotal and variable.

    Cross-Tolerances

    LSD
    60% ●○○
    Psilocybin
    60% ●○○
    Other NBOMes
    80% ●●○
    2C-x
    50% ●○○
    DOx
    50% ●○○

    Experience Report Analysis

    Erowid
    1 Reports
    2014–2014 Date Range

    Demographics

    Gender Distribution

    Reports Over Time

    Real-World Dose Distribution

    62K Doses

    From 3 individual dose entries

    Legal Status

    Country Status Notes
    Sweden The Riksdag added 25H-NBOMe to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 1, 2013, published by Medical Products Agency (MPA) in regulation LVFS 2013:15 listed as 25H-NBOMe, and 2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.
    United Kingdom This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.

    Harm Reduction

    drugs.wiki

    25H-NBOMe is the N-(2‑methoxybenzyl) derivative of the unsubstituted phenethylamine 2C‑H. Compared with the more common halogenated NBOMes (25I/25C/25B), community and in‑vitro discussions indicate it is much weaker at 5‑HT2A and more adrenergic in feel, which encourages multi‑milligram dosing and raises peripheral toxicity risk (tachycardia, hypertension, cold/numb extremities). NBOMes have been repeatedly mis‑sold as LSD on blotter; field checks can help: LSD fluoresces under UV and yields a positive on certain LSD field reagent kits, while NBOMes typically do not. However, taste/numbness and quick field tests are not definitive—use laboratory drug checking where available. Avoid relying on swallowing blotter as a safety test: some NBOMe salts show uncertain oral activity; discard unknown blotters if you wish to avoid NBOMes. Volumetric dosing is strongly recommended for any sub‑milligram or low‑milligram material; label solutions clearly, use appropriate solvent, and calculate carefully. Insufflation of NBOMes is associated with a disproportionate number of medical emergencies; mucosal damage and rapid spikes in BP/HR are common—prefer buccal/sublingual if one uses at all. Set, setting, and body temperature management matter: minimize exertion, take cooling breaks, and sip electrolytes to mitigate hyperthermia risk from the stimulant component. People with cardiovascular disease, uncontrolled hypertension, Raynaud‑type circulation issues, or migraine with vasospasm should avoid NBOMes due to vasoconstriction risk. Because cross‑tolerance within 5‑HT2A agonists is common, allow at least 1–2 weeks between sessions to reduce unpredictable dosing and muted effects. There are anecdotal reports of HPPD after NBOMe use; persistent visual effects are possible even after single exposures. Parenteral routes (IV/IM) are strongly discouraged due to potency, solubility variability, and severe vasoconstriction risk. If severe chest pain, blue/cold digits, intractable vomiting, severe agitation, seizures, or loss of consciousness occur, seek emergency care immediately and avoid taking additional substances while waiting.

    References

    Data Sources

    ← Back to 25H-NBOMe